Dr Reddys Laboratories Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints

The Dr Reddys Laboratories Q1 Results FY27 outlook is anchored on Q4 FY26 verified actuals and Uniresearch analysis applying the 39-analyst FY27 consensus to Q1 FY26 verified actuals. Uniresearch projects Revenue Rs 9,121 Cr (+6.4% YoY) and PAT Rs 1,449 Cr (+2.8% YoY). Prepared by Ankit Jaiswal.

Click Here – Get Free Investment Predictions

Dr Reddys Laboratories Q1 Results FY27 – Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 Results FY27 Uniresearch Prediction	YoY Change	Source
Dr Reddys Laboratories Revenue (Rs Cr)	8,572	9,121	+6.4%	Uniresearch | 39-analyst consensus applied to Q1 FY26 verified actual
PAT (Rs Cr)	1,410	1,449	+2.8%	Uniresearch | 39-analyst consensus applied to Q1 FY26 verified actual
Avg Analyst Target	Rs 1,335	12-month view	–	Analyst consensus (39 analysts)

Predictions apply 39-analyst FY27 consensus (Rev +6.4%, PAT +2.8%) to Q1 FY26 verified actuals. Not guaranteed outcomes.

Dr Reddys Laboratories Q4 FY26 Key Metrics – Baseline for Dr Reddys Laboratories Q1 Results FY27

Metric	Q4 FY26 Actual	YoY Change	Source
Revenue (Rs Cr)	7,546	-11.5% YoY	Consolidated quarterly financial data
PAT (Rs Cr)	221	-86.1% YoY	Consolidated quarterly financial data

What Analysts Are Saying About Dr Reddys Laboratories Q1 Results FY27

Across 39 analysts covering Dr Reddys Laboratories, the FY27 consensus projects revenue growth of +6.4% and profit growth of +2.8%, with an average 12-month price target of Rs 1,335. The Q1 Results FY27 prediction reflects this consensus applied to verified Q1 FY26 actuals.

Key Watchpoints for Dr Reddys Laboratories

Revenue Delivery vs Consensus for Dr Reddys Laboratories

The primary watchpoint is whether Revenue in Q1 Results FY27 delivers in line with the Uniresearch projection of Rs 9,121 Cr (+6.4% consensus growth). Q1 FY26 base was Rs 8,572 Cr.

PAT Performance in Q1 Results FY27

The PAT watchpoint is whether Dr Reddys Laboratories achieves Rs 1,449 Cr (+2.8% growth from Q1 FY26 base of Rs 1,410 Cr). Q4 FY26 PAT was Rs 221 Cr.

Risks to the Dr Reddys Laboratories Prediction

Below-Consensus Revenue Growth

If Revenue comes in below the +6.4% consensus, actual revenue would fall short of Rs 9,121 Cr.

PAT Pressure in Q1 Results FY27

The PAT prediction of Rs 1,449 Cr could be impacted by cost escalation not factored into the 39-analyst consensus of +2.8%.

Conclusion: Dr Reddys Laboratories

The Dr Reddys Laboratories Uniresearch prediction of Revenue Rs 9,121 Cr and PAT Rs 1,449 Cr is derived from the 39-analyst consensus FY27 growth rates applied to verified Q1 FY26 actuals. When Q1 Results FY27 are declared, investors can benchmark actual performance against this consensus prediction. Track live updates on Univest.

Track Dr Reddys Laboratories Live on the Univest Screener

Download the Univest iOS App or Univest Android App for live Q1 Results FY27 alerts.

Frequently Asked Questions on Dr Reddys Laboratories

What is Uniresearch’s PAT prediction for Dr Reddys Laboratories Q1 Results FY27?

Ans. Uniresearch projects Dr Reddys Laboratories PAT at Rs 1,449 Cr, applying 39-analyst FY27 profit growth consensus of +2.8% to Q1 FY26 verified PAT of Rs 1,410 Cr.

What is the Revenue prediction for Dr Reddys Laboratories Q1 Results FY27?

Ans. Dr Reddys Laboratories Revenue is projected at Rs 9,121 Cr, applying +6.4% FY27 revenue consensus to verified Q1 FY26 base.

What were Dr Reddys Laboratories Q1 Results FY27?

Ans. Q4 FY26 consolidated Revenue was Rs 7,546 Cr (-11.5% YoY) and PAT was Rs 221 Cr (-86.1% YoY).

Does the Dr Reddys Laboratories Q1 Results FY27?

Ans. No. All predictions in this article are derived from the 39-analyst consensus applied to verified Q1 FY26 actuals.

What is the analyst target price mentioned in the Dr Reddys Laboratories Q1 Results FY27?

Ans. The 39-analyst consensus gives an average 12-month price target of Rs 1,335 for Dr Reddys Laboratories.

What are the risks to the Dr Reddys Laboratories Q1 Results FY27?

Ans. Risks include below-consensus revenue growth (target: +6.4%) and unexpected cost pressures impacting the +2.8% PAT consensus.

What is the Q1 FY26 base for the Dr Reddys Laboratories Q1 Results FY27?

Ans. Q1 FY26 consolidated Revenue was Rs 8,572 Cr and PAT was Rs 1,410 Cr. These form the base for the Dr Reddys Laboratories prediction.